Pulsed Dye Laser for Treatment of Basal Cell Carcinoma
Background:. Basal cell carcinoma (BCC) is the most common malignancy worldwide. The incidence of BCC is increasing up to 10% per year worldwide. Surgical excision and Mohs surgery are the gold standard treatment modalities. However, patients may not be candidates for surgery. Pulsed dye laser (PDL)...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2023-03-01
|
| Series: | Plastic and Reconstructive Surgery, Global Open |
| Online Access: | http://journals.lww.com/prsgo/fulltext/10.1097/GOX.0000000000004850 |
| _version_ | 1797859649716748288 |
|---|---|
| author | Kelsey L. Baran, DO Tiffany C. Cheung, DO George A. Csank, MD Basil M. Michaels, MD, FACS |
| author_facet | Kelsey L. Baran, DO Tiffany C. Cheung, DO George A. Csank, MD Basil M. Michaels, MD, FACS |
| author_sort | Kelsey L. Baran, DO |
| collection | DOAJ |
| description | Background:. Basal cell carcinoma (BCC) is the most common malignancy worldwide. The incidence of BCC is increasing up to 10% per year worldwide. Surgical excision and Mohs surgery are the gold standard treatment modalities. However, patients may not be candidates for surgery. Pulsed dye laser (PDL) is a novel technique for treating BCC.
Methods:. Patients with biopsy-proven BCC underwent two treatments with PDL at 6-week intervals at Berkshire Cosmetic and Reconstructive Surgery Center. Patients returned 6 weeks after the second treatment for evaluation for response to treatment. Follow-up examinations were conducted at 6, 12, and 18 months after treatment with PDL.
Results:. Twenty patients with 21 biopsy-proven BCCs were treated with PDL at Berkshire Cosmetic and Reconstructive Surgery Center between 2019 and 2021. Nineteen BCCs had a complete response after two treatments, for a clearance rate of 90%. Two of the 21 lesions did not respond for an incomplete response rate of 10%.
Conclusion:. PDL is an effective nonsurgical treatment option in the management of BCC. |
| first_indexed | 2024-04-09T21:32:57Z |
| format | Article |
| id | doaj.art-cf6cd1354a2e492a88e88243c005c104 |
| institution | Directory Open Access Journal |
| issn | 2169-7574 |
| language | English |
| last_indexed | 2024-04-09T21:32:57Z |
| publishDate | 2023-03-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Plastic and Reconstructive Surgery, Global Open |
| spelling | doaj.art-cf6cd1354a2e492a88e88243c005c1042023-03-27T06:47:44ZengWolters KluwerPlastic and Reconstructive Surgery, Global Open2169-75742023-03-01113e485010.1097/GOX.0000000000004850202303000-00012Pulsed Dye Laser for Treatment of Basal Cell CarcinomaKelsey L. Baran, DO0Tiffany C. Cheung, DO1George A. Csank, MD2Basil M. Michaels, MD, FACS3From the * Department of Surgery, Berkshire Medical Center; Pittsfield, Mass.† Department of Surgery, Berkshire Medical Center, Pittsfield, Mass.‡ Department of Plastic Surgery, University of Massachusetts, Berkshire Cosmetic and Reconstructive Surgery Center, Pittsfield, Mass.§ Department of Plastic Surgery, University of Massachusetts, Berkshire Cosmetic and Reconstructive Surgery Center, Pittsfield, Mass.Background:. Basal cell carcinoma (BCC) is the most common malignancy worldwide. The incidence of BCC is increasing up to 10% per year worldwide. Surgical excision and Mohs surgery are the gold standard treatment modalities. However, patients may not be candidates for surgery. Pulsed dye laser (PDL) is a novel technique for treating BCC. Methods:. Patients with biopsy-proven BCC underwent two treatments with PDL at 6-week intervals at Berkshire Cosmetic and Reconstructive Surgery Center. Patients returned 6 weeks after the second treatment for evaluation for response to treatment. Follow-up examinations were conducted at 6, 12, and 18 months after treatment with PDL. Results:. Twenty patients with 21 biopsy-proven BCCs were treated with PDL at Berkshire Cosmetic and Reconstructive Surgery Center between 2019 and 2021. Nineteen BCCs had a complete response after two treatments, for a clearance rate of 90%. Two of the 21 lesions did not respond for an incomplete response rate of 10%. Conclusion:. PDL is an effective nonsurgical treatment option in the management of BCC.http://journals.lww.com/prsgo/fulltext/10.1097/GOX.0000000000004850 |
| spellingShingle | Kelsey L. Baran, DO Tiffany C. Cheung, DO George A. Csank, MD Basil M. Michaels, MD, FACS Pulsed Dye Laser for Treatment of Basal Cell Carcinoma Plastic and Reconstructive Surgery, Global Open |
| title | Pulsed Dye Laser for Treatment of Basal Cell Carcinoma |
| title_full | Pulsed Dye Laser for Treatment of Basal Cell Carcinoma |
| title_fullStr | Pulsed Dye Laser for Treatment of Basal Cell Carcinoma |
| title_full_unstemmed | Pulsed Dye Laser for Treatment of Basal Cell Carcinoma |
| title_short | Pulsed Dye Laser for Treatment of Basal Cell Carcinoma |
| title_sort | pulsed dye laser for treatment of basal cell carcinoma |
| url | http://journals.lww.com/prsgo/fulltext/10.1097/GOX.0000000000004850 |
| work_keys_str_mv | AT kelseylbarando pulseddyelaserfortreatmentofbasalcellcarcinoma AT tiffanyccheungdo pulseddyelaserfortreatmentofbasalcellcarcinoma AT georgeacsankmd pulseddyelaserfortreatmentofbasalcellcarcinoma AT basilmmichaelsmdfacs pulseddyelaserfortreatmentofbasalcellcarcinoma |